Camurus shares rise after Q2 revenue, operating profit beat
BUZZ-Camurus shares rise after Q2 revenue, operating profit beat ** Shares in Camurus CAMX.ST rise 10% after the Swedish biotech reported Q2 results above estimates
** Its revenue reached SEK 702 million ($72.8 million), above IBES estimates of SEK 632.8 million
** Jefferies says revenue beat was driven by sales of injectable opioid-use disorder drugs Brixadi and Buvidal, with $5 million milestone from partnership with Eli Lilly LLY.N already "in the numbers"
** Operating profit for the quarter was SEK 293 million, beating IBES estimate of SEK 232 million
** Higher revenues, with in-line gross margin and operating expenses drove up the operating profit beat, Jefferies says
** Jefferies estimates Camurus will resubmit an application to the FDA for its Oclaiz hormone disorder drug by Q4 this year
** Shares were up 10% at 07:01 GMT, on track for their best day since November 2025 if gains hold
($1 = 9.6490 Swedish crowns)
(Reporting by Vera Dvorakova)
Recent news on Camurus AB
See all newsBrief: Camurus Receives Approval In Canada For Oczyesa XR
Brief: Executive Sells About £279,000 Of Camurus Shares
Jefferies cuts Ipsen to 'underperform' on Somatuline competition risk
Brief: Camurus Says NDA Resubmission For CAM2029 In Acromegaly Accepted For Review By FDA
Camurus shares rise after Q2 revenue, operating profit beat